SCHEMBL20255697

SCHEMBL20255697

O=C(O)CNC(=O)Cc1csc(-c2ccc3c(c2)OCCO3)n1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SHMT2 P34897 7/20 0.66
▸ SHMT1 P34896 5/20 0.66
▸ KDM4E B2RXH2 3/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ EGLN1 Q9GZT9 1/20 0.48
▸ LMNA P02545 5/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ GAA P10253 2/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20255802 0.93 SHMT2 (0.61) SHMT2SHMT1KDM4EEGLN1LMNA
SCHEMBL31578642 0.85 SHMT2 (0.55) SHMT2SHMT1KDM4EEGLN1LMNA
SCHEMBL20255445 0.80 SHMT2 (0.74) SHMT2SHMT1KDM4ELMNAALDH1A1
SCHEMBL31578929 0.80 SHMT2 (0.71) SHMT2SHMT1KDM4EEGLN1LMNA
SCHEMBL20255599 0.80 SHMT2 (1.00) SHMT2SHMT1KDM4EMAPK1LMNA
SCHEMBL20255622 0.80 LMNA (0.73) SHMT2SHMT1KDM4ELMNAALDH1A1
SCHEMBL20255444 0.80 SHMT2 (0.68) SHMT2SHMT1KDM4ELMNAALDH1A1
SCHEMBL21560039 0.80 SHMT2 (0.72) SHMT2SHMT1KDM4EEGLN1LMNA
SCHEMBL20255564 0.79 SHMT2 (0.67) SHMT2SHMT1KDM4EEGLN1LMNA
SCHEMBL20255558 0.79 SHMT2 (0.70) SHMT2SHMT1KDM4EEGLN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091451-B2 SHMT inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-08-17 — — US disclosed
US-11091451-B2 SHMT inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-08-17 — — US disclosed
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-11-14 — — US disclosed
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-11-14 — — US disclosed
WO-2018106636-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2018-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091451-B2 SHMT inhibitors and uses thereof SHMT1, SHMT2, BHMT SHMT2 2/4885SHMT1 1/4885KDM4E 344/4885
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF SHMT1, SHMT2, BHMT SHMT2 2/4885SHMT1 1/4885KDM4E 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback